S&P 500   3,348.46 (+0.62%)
DOW   27,368.43 (+0.61%)
QQQ   274.64 (+1.32%)
AAPL   456.57 (+3.71%)
MSFT   216.04 (+1.46%)
FB   266.15 (+6.84%)
GOOGL   1,505.40 (+1.78%)
AMZN   3,237.00 (+1.00%)
NVDA   454.00 (+0.56%)
CGC   17.71 (-7.81%)
BABA   264.20 (-0.27%)
TSLA   1,503.38 (+1.24%)
MU   48.75 (-4.51%)
GE   6.38 (-0.31%)
AMD   86.73 (+1.66%)
T   29.83 (-0.07%)
F   6.98 (+0.29%)
ACB   10.28 (-4.01%)
GILD   68.97 (-0.04%)
NFLX   509.70 (+1.51%)
DIS   131.59 (+3.12%)
BAC   25.44 (+0.20%)
BA   172.23 (-1.18%)
S&P 500   3,348.46 (+0.62%)
DOW   27,368.43 (+0.61%)
QQQ   274.64 (+1.32%)
AAPL   456.57 (+3.71%)
MSFT   216.04 (+1.46%)
FB   266.15 (+6.84%)
GOOGL   1,505.40 (+1.78%)
AMZN   3,237.00 (+1.00%)
NVDA   454.00 (+0.56%)
CGC   17.71 (-7.81%)
BABA   264.20 (-0.27%)
TSLA   1,503.38 (+1.24%)
MU   48.75 (-4.51%)
GE   6.38 (-0.31%)
AMD   86.73 (+1.66%)
T   29.83 (-0.07%)
F   6.98 (+0.29%)
ACB   10.28 (-4.01%)
GILD   68.97 (-0.04%)
NFLX   509.70 (+1.51%)
DIS   131.59 (+3.12%)
BAC   25.44 (+0.20%)
BA   172.23 (-1.18%)
S&P 500   3,348.46 (+0.62%)
DOW   27,368.43 (+0.61%)
QQQ   274.64 (+1.32%)
AAPL   456.57 (+3.71%)
MSFT   216.04 (+1.46%)
FB   266.15 (+6.84%)
GOOGL   1,505.40 (+1.78%)
AMZN   3,237.00 (+1.00%)
NVDA   454.00 (+0.56%)
CGC   17.71 (-7.81%)
BABA   264.20 (-0.27%)
TSLA   1,503.38 (+1.24%)
MU   48.75 (-4.51%)
GE   6.38 (-0.31%)
AMD   86.73 (+1.66%)
T   29.83 (-0.07%)
F   6.98 (+0.29%)
ACB   10.28 (-4.01%)
GILD   68.97 (-0.04%)
NFLX   509.70 (+1.51%)
DIS   131.59 (+3.12%)
BAC   25.44 (+0.20%)
BA   172.23 (-1.18%)
S&P 500   3,348.46 (+0.62%)
DOW   27,368.43 (+0.61%)
QQQ   274.64 (+1.32%)
AAPL   456.57 (+3.71%)
MSFT   216.04 (+1.46%)
FB   266.15 (+6.84%)
GOOGL   1,505.40 (+1.78%)
AMZN   3,237.00 (+1.00%)
NVDA   454.00 (+0.56%)
CGC   17.71 (-7.81%)
BABA   264.20 (-0.27%)
TSLA   1,503.38 (+1.24%)
MU   48.75 (-4.51%)
GE   6.38 (-0.31%)
AMD   86.73 (+1.66%)
T   29.83 (-0.07%)
F   6.98 (+0.29%)
ACB   10.28 (-4.01%)
GILD   68.97 (-0.04%)
NFLX   509.70 (+1.51%)
DIS   131.59 (+3.12%)
BAC   25.44 (+0.20%)
BA   172.23 (-1.18%)
Log in

NASDAQ:ARVNArvinas Stock Price, Forecast & News

$29.60
-1.07 (-3.49 %)
(As of 08/6/2020 03:32 PM ET)
Add
Compare
Today's Range
$29.48
Now: $29.60
$30.66
50-Day Range
$29.88
MA: $33.18
$36.34
52-Week Range
$15.19
Now: $29.60
$61.57
Volume6,911 shs
Average Volume299,993 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.98 million
Book Value$6.72 per share

Profitability

Net Income$-70,290,000.00
Net Margins-182.59%

Miscellaneous

Employees83
Market Cap$1.16 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$29.60
-1.07 (-3.49 %)
(As of 08/6/2020 03:32 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arvinas (NASDAQ:ARVN) Frequently Asked Questions

How has Arvinas' stock been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARVN shares have decreased by 32.1% and is now trading at $29.90.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Arvinas?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas
.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Arvinas
.

How were Arvinas' earnings last quarter?

Arvinas Inc (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.06. Arvinas had a negative net margin of 182.59% and a negative return on equity of 31.97%.
View Arvinas' earnings history
.

What price target have analysts set for ARVN?

11 brokerages have issued 1-year target prices for Arvinas' stock. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $57.10 in the next year. This suggests a possible upside of 91.0% from the stock's current price.
View analysts' price targets for Arvinas
.

Has Arvinas been receiving favorable news coverage?

News headlines about ARVN stock have trended somewhat positive on Thursday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arvinas earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Arvinas
.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,300,000 shares, an increase of 13.8% from the June 15th total of 2,900,000 shares. Based on an average daily volume of 608,400 shares, the short-interest ratio is currently 5.4 days. Approximately 12.9% of the company's stock are sold short.
View Arvinas' Current Options Chain
.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
  • Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
  • Dr. Ian Taylor, Chief Scientific Officer (Age 56)
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Andrew Crew, Chief Technology Officer (Age 54)

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.93%), Rossmore Private Capital (0.26%), First Trust Advisors LP (0.11%), Swiss National Bank (0.11%), Principal Financial Group Inc. (0.06%) and UBS Group AG (0.06%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas
.

Which institutional investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Rossmore Private Capital, and Russell Investments Group Ltd.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, and Sean A Cassidy.
View insider buying and selling activity for Arvinas
.

Which institutional investors are buying Arvinas stock?

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Principal Financial Group Inc., First Trust Advisors LP, UBS Group AG, Quantitative Systematic Strategies LLC, Swiss National Bank, Strs Ohio, and ProShare Advisors LLC. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $29.90.

How big of a company is Arvinas?

Arvinas has a market capitalization of $1.17 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.